QBiotics’ first USA shipment of STELFONTA®

24 February 2021

QBiotics Group has delivered the first shipment of STELFONTA® (tigilanol tiglate injection) to its USA marketing and distribution partner, Virbac, for sale to veterinary oncologists and primary care veterinarians across the U.S. The shipment was received by Virbac on Tuesday, 23 February, 2021.

This milestone comes after STELFONTA® was approved as a veterinary pharmaceutical by the US Food and Drug Administration - Center for Veterinary Medicine in November 2020, for the treatment of all grades of non-metastatic mast cell tumours (MCT) in dogs.